Mechanism of miR‑98 inhibiting tumor proliferation and invasion by targeting IGF1R in diabetic patients combined with colon cancer

Liu,Shixiong; Zhou,Yun; Zhou,Yongning; Wang,Jing; Ji,Rui

doi:10.3892/ol.2020.11707

Mechanism of miR‑98 inhibiting tumor proliferation and invasion by targeting IGF1R in diabetic patients combined with colon cancer

Authors:
- Shixiong Liu
- Yun Zhou
- Yongning Zhou
- Jing Wang
- Rui Ji
View Affiliations

Affiliations: Department of Geriatrics (II), The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: June 9, 2020 https://doi.org/10.3892/ol.2020.11707
Pages: 1719-1726
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression level of miR‑98 in diabetic colon cancer (CRC) tissues and the regulation mechanism of colon cancer cell proliferation and invasion ability were studied. Forty patients with type 2 diabetes mellitus complicated with colon cancer, 40 colon cancer patients, and 40 patients with diabetic colonoscopy were enrolled between January 2017 and January 2018. Real‑time quantitative PCR was used to detect the expression level of miR‑98. After SW480 cells were transfected with miR‑98 mimics or control simulants, the proliferation of cancer cells was detected by MTT assay, and the invasion ability of cancer cells was detected by Transwell cell invasion assay. The dual luciferase assay was used to detect the binding relationship between miR‑98 and IGF1R. Western blot analysis was used to detect the expression of IGF1R protein in tumor tissues of patients with diabetes mellitus and colon cancer. Compared with diabetic patients, the expression level of miR‑98 was decreased in colon cancer patients. Compared with tumor tissues of colon cancer patients, the expression level of miR‑98 was significantly decreased in diabetic colon cancer tissues. Compared with the commonly cultured colon cancer SW480 cells, the expression level of miR‑98 was significantly decreased in SW480 cells cultured under high glucose conditions. Increased expression of miR‑98 inhibits colon cancer cell proliferation and invasion. miR‑98 can target and bind to IGF1R and inhibit its expression level. IGF1R is upregulated in diabetic colon cancer tissue. miR‑98 inhibits proliferation and invasion of diabetic colon cancer by targeting IGF1R. The expression level of miR‑98 in diabetic colon cancer tissues is lower than that in colon cancer tissues. miR‑98 can inhibit the proliferation and invasion of colon cancer cells by targeting the target gene IGF1R. miR‑98 may be a potential biological target for the treatment of patients with diabetes and colon cancer.

View Figures

View References

1	Peng YC, Lin CL, Hsu WY, Chang CS, Yeh HZ, Liao SC and Kao CH: The risk of colorectal cancer is related to frequent hospitalization of IBD in an Asian population: results from a nationwide study. QJM. 108:457–463. 2015. View Article : Google Scholar : PubMed/NCBI
2	Belov L, Zhou J and Christopherson RI: Colorectal cancer thera-peutic antibodies. Encyclopedia of Cancer. Schwab M: Springer. (Berlin, Heidelberg). 944–948. 2014.PubMed/NCBI
3	Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, et al: The clinical and biological significance of miR-224 expression in colorectal cancer metastasis. Gut. 65:977–989. 2016. View Article : Google Scholar : PubMed/NCBI
4	Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 17:79–92. 2017. View Article : Google Scholar : PubMed/NCBI
5	Al Omari A, Abdelkhaleq H, Al-Hussaini M, Turfa R, Awad N, Hassan MM, Alfaqih MA and Garrett CR: Validation of the survival benefits of metformin in middle Eastern patients with type II diabetes mellitus and colorectal cancer. J Glob Oncol. 4:1–10. 2018. View Article : Google Scholar
6	Park JW, Lee JH, Park YH, Park SJ, Cheon JH, Kim WH and Kim TI: Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. World J Gastroenterol. 23:5196–5205. 2017. View Article : Google Scholar : PubMed/NCBI
7	Nakayama Y, Iijima T, Wakaume R, Takahashi K, Matsumoto H, Nakano D, Miyaki M and Yamaguchi T: Microsatellite instability is inversely associated with type 2 diabetes mellitus in colorectal cancer. PLoS One. 14:e02155132019. View Article : Google Scholar : PubMed/NCBI
8	Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI
9	Berster JM and Göke B: Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem. 114:84–98. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jin T: Why diabetes patients are more prone to the development of colon cancer? Med Hypotheses. 71:241–244. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wu YZ, Chan KYY, Leung KT, Lam HS, Tam YH, Lee KH, Li K and Ng PC: Dysregulation of miR-431 and target gene FOXA1 in intestinal tissues of infants with necrotizing enterocolitis. FASEB J. 33:5143–5152. 2019. View Article : Google Scholar : PubMed/NCBI
12	Shen B, Han S, Wang Y, Yang Z, Zou Z, Liu J, Zhao Z, Wu R and Wang C: Bta-miR-152 affects intracellular triglyceride content by targeting the UCP3 gene. J Anim Physiol Anim Nutr (Berl). 103:1365–1373. 2019. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Zhang M, Guo Q, Hu X, Zhao Z, Ni L, Liu L, Wang X, Wang Z, Tong D, et al: MicroRNA-1297 inhibits proliferation and promotes apoptosis in gastric cancer cells by downregulating CDC6 expression. Anticancer Drugs. 30:803–811. 2019. View Article : Google Scholar : PubMed/NCBI
14	Ghaemi Z, Soltani BM and Mowla SJ: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway. Front Oncol. 9:6532019. View Article : Google Scholar : PubMed/NCBI
15	Yun Z, Meng F, Jiang P, Yue M and Li S: microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA. Cancer Manag Res. 11:5821–5834. 2019. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Huang Y, Cheng Q, Wang J, Zuo J, Liang Y and Yuan G: miR-1-3p suppresses the epithelial-mesenchymal transition property in renal cell cancer by downregulating Fibronectin 1. Cancer Manag Res. 11:5573–5587. 2019. View Article : Google Scholar : PubMed/NCBI
17	Wang X, An D, Liu X, Wang X and Li B: MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma. OncoTargets Ther. 12:5967–5977. 2019. View Article : Google Scholar : PubMed/NCBI
18	Zhu W, Luo X, Fu H, Liu L, Sun P and Wang Z: miR-3653 inhibits the metastasis and epithelial-mesenchymal transition of colon cancer by targeting Zeb2. Pathol Res Pract. 215:1525772019. View Article : Google Scholar : PubMed/NCBI
19	Chai B, Guo Y, Cui X, Liu J, Suo Y, Dou Z and Li N: miR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. Am J Transl Res. 11:4516–4523. 2019.PubMed/NCBI
20	Jin Y, Cheng H, Cao J and Shen W: MicroRNA 32 promotes cell proliferation, migration, and suppresses apoptosis in colon cancer cells by targeting OTU domain containing 3. J Cell Biochem. 120:18629–18639. 2019. View Article : Google Scholar : PubMed/NCBI
21	Shi XY, Wang H, Wang W and Gu YH: miR-98-5p regulates proliferation and metastasis of MCF-7 breast cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci. 23:2847–2855. 2019.PubMed/NCBI
22	Tan H, Zhu G, She L, Wei M, Wang Y, Pi L, Chen C, Zhang D, Tan P, Chen J, et al: miR-98 inhibits malignant progression via targeting MTDH in squamous cell carcinoma of the head and neck. Am J Cancer Res. 7:2554–2565. 2017.PubMed/NCBI
23	Zhu W, Huang Y, Pan Q, Xiang P, Xie N and Yu H: MicroRNA-98 suppress Warburg effect by targeting HK2 in colon cancer cells. Dig Dis Sci. 62:660–668. 2017. View Article : Google Scholar : PubMed/NCBI
24	Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, et al Diabetes Cancer Connect Consortium, : Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. Mol Oncol. 13:857–872. 2019. View Article : Google Scholar : PubMed/NCBI
25	Wang L, Bai YY, Yang Y, Hu F, Wang Y, Yu Z, Cheng Z and Zhou J: Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway. Oncotarget. 7:38539–38550. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wang K, Dong L, Fang Q, Xia H and Hou X: Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark. 20:283–288. 2017. View Article : Google Scholar : PubMed/NCBI
27	Zhou H, Huang Z, Chen X and Chen S: miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. Biomed Pharmacother. 89:1453–1461. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zhu M, Zhang C, Chen D, Chen S and Zheng H: MicroRNA-98-HMGA2-POSTN signal pathway reverses epithelial-to-mesenchymal transition in laryngeal squamous cell carcinoma. Biomed Pharmacother. 117:1089982019. View Article : Google Scholar : PubMed/NCBI
29	Li W, Wang J, Zhang D, Zhang X, Xu J and Zhao L: MicroRNA-98 targets HMGA2 to inhibit the development of retinoblastoma through mediating Wnt/β-catenin pathway. Cancer Biomark. 25:79–88. 2019. View Article : Google Scholar : PubMed/NCBI
30	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer - a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
31	Liu J, Bian T, Feng J, Qian L, Zhang J, Jiang D, Zhang Q, Li X, Liu Y and Shi J: miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β. Cancer Sci. 109:289–296. 2018. View Article : Google Scholar : PubMed/NCBI
32	Ma L, Chen X, Li C, Cheng R, Gao Z, Meng X, Sun C, Liang C and Liu Y: miR-129-5p and −3p co-target WWP1 to suppress gastric cancer proliferation and migration. J Cell Biochem. Nov 11–2018.(Epub ahead of print). doi: 10.1002/jcb.28027.
33	Kumar AS, Rayala SK and Venkatraman G: Targeting IGF1R pathway in cancer with microRNAs: How close are we? RNA Biol. 15:320–326. 2018. View Article : Google Scholar : PubMed/NCBI